Evaluation and management of osteoporosis in liver disease.
This article discusses the clinical importance of hepatic osteopenia, the identification of risk factors for the individual patient, and the selection of patients, timing, and methods for diagnostic screening. General supportive measures to maximize bone health should be used in all patients at risk. In addition, for the patient with established osteoporosis, specific therapeutic measures may be justified, despite the lack of adequate randomized trials of these agents in patients with hepatic osteopenia.
Hay
J Eileen
JE
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55905, USA. jhay@mayo.edu
Guichelaar
Maureen M J
MM
D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000628:therapy; D004164:Diphosphonates / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000150:complications*; D016031:Liver Transplantation; D008297:Male; D010024:Osteoporosis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D012307:Risk Factors
D004164:Diphosphonates